SCHEMBL7704872

SCHEMBL7704872

COc1cccc(CN(Cc2ccc3c(c2)NC(N)=C(C)O3)C(=O)OC(C)(C)C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B2 P37059 3/20 0.38
SLC2A1 P11166 5/20 0.36
SLC2A4 P14672 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
NCOR2 Q9Y618 1/20 0.36
TSPO P30536 1/20 0.36
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
PTGES O14684 1/20 0.35
LPAR1 Q92633 1/20 0.35
LPAR5 Q9H1C0 1/20 0.35
ROCK2 O75116 2/20 0.34
TAS2R14 Q9NYV8 1/20 0.34
ROCK1 Q13464 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7704946 0.92 ALDH1A1 (0.38) SLC2A1HDAC3HDAC1HDAC2NCOR2
SCHEMBL7704910 0.90 HDAC1 (0.45) HDAC3HDAC1HDAC2NCOR2MEN1
SCHEMBL7711248 0.88 RIPK1 (0.37) HDAC3HDAC1HDAC2NCOR2TSPO
SCHEMBL7704902 0.88 RIPK1 (0.37) SLC2A1HDAC3HDAC1HDAC2NCOR2
SCHEMBL7711186 0.87 NR3C2 (0.41) SLC2A1HDAC3HDAC1HDAC2NCOR2
SCHEMBL7711366 0.87 HDAC1 (0.37) HDAC3HDAC1HDAC2NCOR2ALDH1A1
SCHEMBL7708189 0.87 HDAC3 (0.37) HDAC3HDAC1HDAC2NCOR2MEN1
SCHEMBL7711360 0.86 TRPM8 (0.36) SLC2A1HDAC3HDAC1HDAC2NCOR2
SCHEMBL7713369 0.85 HDAC1 (0.34) HDAC3HDAC1HDAC2NCOR2ALOX15
SCHEMBL6302692 0.85 BRD4 (0.38) HDAC3HDAC1HDAC2NCOR2PTGES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed